Table 2.
The characteristics of the 4 eligible studies evaluating haemangioma response
| Studies | Design | Age (mo) | Duration of treatment (mo) | Regimen | n | Diseased region | Outcome | AE | ||
|---|---|---|---|---|---|---|---|---|---|---|
| Class 1 | Class 2 | Class 3 | ||||||||
| Luo 201328 | CS | 1–12 | 3 | Topical timolol maleate solution, 3 times daily | 89 | 51 head and face, 22 extremities, 16 trunk | 7 | 31 | 51 | 0 |
| 1–12 | 3 | Observation | 20 | NA | 13 | 6 | 1 | NA | ||
| Yu 201529 | CS | 1–18 | 6 | Topical timolol maleate solution, 3–4 times daily | 176 | 87 head and face or neck, 54 extremities, 22 trunk, 13 perineum | 14 | 60 | 102 | 4 |
| 2–11 | 6 | Observation | 34 | NA | 17 | 13 | 4 | NA | ||
| Chambers 201216 | CS | NA | 2 | Topical 0.25% timolol maleate gel, twice daily | 5 | NA | 0 | 0 | 5 | 0 |
| NA | 2 | Observation | 4 | NA | 3 | 0 | 1 | NA | ||
| Yu 201330 | CS | 1–12 | NA | Topical 0.5% timolol maleate solution, 3 times daily | 101 | 65 head and face or neck, 27 extremities, 32 trunk | 8 | 36 | 57 | 0 |
| 1–12 | NA | Observation | 23 | 15 | 7 | 1 | NA | |||
NA, not reported; AE, adverse events; CS, cohort study